We describe here, in TNBC and HER2-positive cancer patients, the largest set to date of cancer-free and involved axillary LNs with matched primary tumors and show that humoral, systemic immune responses at the time of primary surgery have prognostic value. The gene discussed is ERBB2; the disease is cancer.